TrialThe New England journal of medicine2025
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
Arun J Sanyal et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
580 papers cite itlatest 60 shown
this paperpooled ittrialcites it